BACKGROUND: This study evaluated 1-h plasma glucose (1HrPG) levels during an oral glucose tolerance test (OGTT) in predicting progression to diabetes and prediabetes among individuals with normal glucose tolerance (NGT). SUBJECTS AND METHODS: After analyzing the electronic records of 32,809 subjects who had undergone an OGTT, we identified 1,179 subjects who had NGT at baseline, defined as fasting plasma glucose (FPG) of < 100 mg/dL and 2-h plasma glucose (2HrPG) of < 140 mg/dL, who had at least one follow-up OGTT. Receiver operating characteristic curves were constructed to derive the optimal 1HrPG values, which were associated with the development of diabetes (FPG of ≥ 126 mg/dL or 2HrPG of ≥ 200 mg/dL) or prediabetes (FPG ≥ 100 to <1 26 mg/dL or 2HrPG of ≥ 140 to < 200 mg/dL) at follow-up in these NGT subjects. RESULTS: On follow-up, 148 (12.6%) subjects developed diabetes, and 392 (33.2%) developed prediabetes. In those with 1HrPG values ≥ 155 mg/dL, 19.5% converted to diabetes compared with 10% among those with 1HrPG of ≥143 to < 155 mg/dL and 6.6% in those with 1HrPG < 143 mg/dL. Comparative figures for conversion to prediabetes were 52.2% (1HrPG values ≥ 155 mg/dL), 39.3% (1HrPG ≥ 143 to <155 mg/dL), and 26.0% (1HrPG < 143 mg/dL). The time to development of diabetes (mean ± SE) was also significantly shorter among those with 1HrPG values of ≥ 155 mg/dL (9.0±0.3 years) compared with those with 1HrPG ≥ 143 to < 155 mg/dL (10.6 ± 0.5 years) and 1HrPG < 143 mg/dL (11.6 ± 0.2 years). CONCLUSIONS: Among NGT subjects with elevated 1HrPG values during an OGTT, progression to diabetes and prediabetes is greater, and the rate of progression is also faster.
BACKGROUND: This study evaluated 1-h plasma glucose (1HrPG) levels during an oral glucose tolerance test (OGTT) in predicting progression to diabetes and prediabetes among individuals with normal glucose tolerance (NGT). SUBJECTS AND METHODS: After analyzing the electronic records of 32,809 subjects who had undergone an OGTT, we identified 1,179 subjects who had NGT at baseline, defined as fasting plasma glucose (FPG) of < 100 mg/dL and 2-h plasma glucose (2HrPG) of < 140 mg/dL, who had at least one follow-up OGTT. Receiver operating characteristic curves were constructed to derive the optimal 1HrPG values, which were associated with the development of diabetes (FPG of ≥ 126 mg/dL or 2HrPG of ≥ 200 mg/dL) or prediabetes (FPG ≥ 100 to <1 26 mg/dL or 2HrPG of ≥ 140 to < 200 mg/dL) at follow-up in these NGT subjects. RESULTS: On follow-up, 148 (12.6%) subjects developed diabetes, and 392 (33.2%) developed prediabetes. In those with 1HrPG values ≥ 155 mg/dL, 19.5% converted to diabetes compared with 10% among those with 1HrPG of ≥143 to < 155 mg/dL and 6.6% in those with 1HrPG < 143 mg/dL. Comparative figures for conversion to prediabetes were 52.2% (1HrPG values ≥ 155 mg/dL), 39.3% (1HrPG ≥ 143 to <155 mg/dL), and 26.0% (1HrPG < 143 mg/dL). The time to development of diabetes (mean ± SE) was also significantly shorter among those with 1HrPG values of ≥ 155 mg/dL (9.0±0.3 years) compared with those with 1HrPG ≥ 143 to < 155 mg/dL (10.6 ± 0.5 years) and 1HrPG < 143 mg/dL (11.6 ± 0.2 years). CONCLUSIONS: Among NGT subjects with elevated 1HrPG values during an OGTT, progression to diabetes and prediabetes is greater, and the rate of progression is also faster.
Authors: A Tumminia; A Milluzzo; F Cinti; M Parisi; F Tata; F Frasca; L Frittitta; R Vigneri; L Sciacca Journal: J Endocrinol Invest Date: 2017-10-24 Impact factor: 4.256
Authors: Adam Hulman; Unjali P Gujral; K M Venkat Narayan; Rajendra Pradeepa; Deepa Mohan; Ranjit Mohan Anjana; Viswanathan Mohan; Kristine Færch; Daniel R Witte Journal: Diabetes Res Clin Pract Date: 2017-02-17 Impact factor: 5.602
Authors: Vanessa Guerreiro; Isabel Maia; João Sérgio Neves; Daniela Salazar; Maria João Ferreira; Fernando Mendonça; Maria Manuel Silva; Marta Borges-Canha; Sara Viana; Cláudia Costa; Jorge Pedro; Ana Varela; Eva Lau; Paula Freitas; Davide Carvalho Journal: Diabetol Metab Syndr Date: 2022-07-06 Impact factor: 5.395
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602
Authors: Tae Jung Oh; Se Hee Min; Chang Ho Ahn; Eun Ky Kim; Soo Heon Kwak; Hye Seung Jung; Kyong Soo Park; Young Min Cho Journal: Diabetes Metab J Date: 2015-03-09 Impact factor: 5.376